Cancer therapy costs influence treatment: a national survey of oncologists
- PMID: 20048377
- DOI: 10.1377/hlthaff.2009.0077
Cancer therapy costs influence treatment: a national survey of oncologists
Abstract
A national survey of medical oncologists indicates that rising cancer treatment costs are influencing clinical practice, even as oncologists tend not to communicate with patients about costs. The survey shows that 84 percent of oncologists say that patients' out-of-pocket spending influences treatment recommendations. Only 43 percent always or frequently discuss costs with patients. Among those surveyed, 79 percent favor more comparative effectiveness research; 80 percent support more cost-effectiveness data, although only 42 percent feel well prepared to interpret it. The results suggest that physicians support federally funded comparative effectiveness research but that they wish to retain a central role in making decisions about how and when to use expensive cancer treatments. The results also support educating physicians about cost-effectiveness and how to communicate with patients regarding cost.
Similar articles
-
Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.J Clin Oncol. 2010 Sep 20;28(27):4149-53. doi: 10.1200/JCO.2010.29.1625. Epub 2010 Aug 9. J Clin Oncol. 2010. PMID: 20697077
-
Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey.J Clin Oncol. 2007 Jan 10;25(2):233-7. doi: 10.1200/JCO.2006.09.2437. J Clin Oncol. 2007. PMID: 17210946 Review.
-
Cost issues in new disease-modifying treatments for advanced cancer: in-depth interviews with physicians.Eur J Cancer. 2007 Sep;43(13):1983-9. doi: 10.1016/j.ejca.2007.05.017. Epub 2007 Jul 9. Eur J Cancer. 2007. PMID: 17616456
-
Do oncologists believe new cancer drugs offer good value?Oncologist. 2006 Feb;11(2):90-5. doi: 10.1634/theoncologist.11-2-90. Oncologist. 2006. PMID: 16476830
-
The negative impact of stark law exemptions on graduate medical education and health care costs: the example of radiation oncology.Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1289-94. doi: 10.1016/j.ijrobp.2009.11.061. Int J Radiat Oncol Biol Phys. 2010. PMID: 20338471 Review.
Cited by
-
Prevalence of Financial Considerations Documented in Primary Care Encounters as Identified by Natural Language Processing Methods.JAMA Netw Open. 2019 Aug 2;2(8):e1910399. doi: 10.1001/jamanetworkopen.2019.10399. JAMA Netw Open. 2019. PMID: 31469397 Free PMC article.
-
Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective.J Manag Care Spec Pharm. 2019 Feb;25(2):246-259. doi: 10.18553/jmcp.2019.25.2.246. J Manag Care Spec Pharm. 2019. PMID: 30698093 Free PMC article. Review.
-
Impact of anticancer drugs price cut on physician's prescription choices on first-line chemotherapy regimens and health expenditure for advanced non-small cell lung cancer in China.J Thorac Dis. 2016 Oct;8(10):2832-2842. doi: 10.21037/jtd.2016.09.35. J Thorac Dis. 2016. PMID: 27867559 Free PMC article.
-
A review of cost communication in oncology: Patient attitude, provider acceptance, and outcome assessment.Cancer. 2017 May 15;123(6):928-939. doi: 10.1002/cncr.30423. Epub 2016 Nov 28. Cancer. 2017. PMID: 27893929 Free PMC article. Review.
-
Cancer's next frontier: addressing high and increasing costs.JAMA. 2010 Mar 17;303(11):1086-7. doi: 10.1001/jama.2010.283. JAMA. 2010. PMID: 20233828 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical